Most "trading gurus" claim some incredible win rate. 80%. 90%. Whatever sounds good.

Almost none of them will let you check.

Joel Peterson is different. The trade plans he calls inside his program are published on a public record anyone can verify - including you, before you ever pay him a dollar.

That was the part that convinced me he's the real deal.

When he says his system calls trades with a verifiable 74-78% win rate, you don't have to take his word for it. You can go look at the record yourself.

If you haven't grabbed your seat for his free workshop this week, here's the link:

👉 [Save your free seat →]

He'll walk you through the full framework - including:

• TCC Sentinel - the proprietary engine behind those trade plans (never shown publicly before)
• His Cycle Pro Dashboard that tells you when to enter and exit big positions
• WaveBot Automation that runs trade plans 24/7 in the background

Plus three free gifts for showing up and staying to the end: $10 in Bitcoin, a free weekly trade setup, and his personal Trade Planner indicator.

👉 [Pick your session →]

P.S. - Bitcoin's last complete cycle ran about 665% from low to high. Most people who held through it ended up close to break-even because they bought high and sold low. Joel's dashboard catches those moves without the emotion. Worth the 75 minutes just for that part.

Hims & Hers’ Revenue Beat Came With a Profitability Problem

Author: Jessica Mitacek. Date Posted: 8/12/2026.

After recently receiving the unwelcome news that Hims & Hers Health (NYSE: HIMS) was being sued by the U.S. Federal Trade Commission (FTC), California, and Utah, investors were dealt another blow on Monday, Aug. 10.

The telehealth platform, which provides direct-to-consumer (D2C) personal care products and virtual medical services, reported its Q2 results, which included its second consecutive earnings miss and its fourth in the past five quarters.

Hims & Hers Sees Big Revenue Gain, Raises Full-Year Guidance

Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)

A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.

This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.

Click here to learn this company's name for free today

On a positive note, Hims & Hers saw an acceleration in both revenue and subscriber growth during Q2. Revenue of $753.21 million exceeded analyst expectations of $698.9 million and represented an increase of more than 38% year over year (YOY). Management raised its full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion.

The company gained roughly 300,000 new subscribers, bringing its total to nearly 3 million. Additionally, Hims & Hers’ investment in AI is beginning to bear fruit. The company reported early benefits from its AI-native care platform, including a threefold increase in customer messaging, an approximately 50% reduction in nonclinical support tasks, and lower cancellation rates in pilot cohorts. Management expects its AI investments to pay back within 12 to 18 months while supporting improved retention and cost efficiency.

The June acquisition of Australia-based Eucalyptus was also a major growth driver, with international revenue increasing more than 17-fold YOY to $131 million. Hims & Hers expects that figure to grow to at least $600 million for the full year while expanding its U.S. specialties—such as testosterone, sexual health, and dermatology—into overseas markets. The acquisition, valued at up to $1.15 billion, targeted not only expansion into Australia and Japan but also a deeper presence in the United Kingdom, Germany, Ireland, and Canada.

According to CFO Yemi Okupe’s comments on the earnings call, the company expects its testosterone segment to become its sixth U.S. specialty, reaching a $100 million annual revenue run rate. Hims & Hers also announced that Dr. Anant Vinjamoori joined as chief medical officer of the Hims brand in June to guide clinical strategy. Meanwhile, the company’s network has grown to more than 1,600 providers across its global operations.

Earnings Continue to Be a Cause for Concern

Despite strong subscriber growth and 38% YOY revenue growth, the Q2 report had areas of concern. Namely, Q2 earnings per share (EPS) of negative 37 cents missed the consensus forecast of negative 5 cents and marked a notable YOY decline from Q2 2025’s EPS of 17 cents.

Notably, profitability and cash flow were under near-term pressure from the business mix and one-time costs, contributing to the stock’s after-hours decline. Adjusted gross margin fell to 64%, down approximately six percentage points from the previous quarter.

While branded GLP-1 weight-loss products and international revenue grew, Q2 free cash flow was negative $68 million. The company also incurred approximately $81 million in acquisition, restructuring, and FTC-related legal costs.

Management also said international operations may remain near breakeven as it continues investing for scale. According to CEO Andrew Dudum, the company is “playing offense,” which he expects will pay off in the long term. Dudum added that those moves—including the Eucalyptus acquisition and a strategic partnership with Novo Nordisk (NYSE: NVO), maker of semaglutide brands Ozempic and Wegovy—leverage Hims & Hers’ leadership position in digital telehealth platforms to deliver more value to customers at better prices, which in turn drives customer acquisition.

Short-Term Hurdles Continue to Cloud Wall Street’s Outlook

The FTC suit adds another potential source of financial pressure. Hims & Hers reported a Q2 net loss of $86.3 million, narrowing from a $92.1 million loss in Q1, while also recording $47.5 million in legal contingencies during the quarter.

Accordingly, Wall Street is exercising caution. HIMS currently carries a consensus Hold rating, with only four of the 16 analysts covering the stock assigning it a Buy rating. The average price target of $32.43 suggests limited upside from current levels, while institutional ownership has seen nearly equal inflows ($1.65 billion) and outflows ($1.34 billion) over the past year.

Meanwhile, the stock remains a favorite among bears. The latest reported short interest now exceeds 30% of the float, or 61.4 million shares valued at $2.29 billion. Perhaps most concerning, insider trading has seen just one buy in the past year, valued at $1.17 million, compared with eight sales totaling more than $50 million.

The market will want the company to improve its profitability after Q2 produced a net loss equal to about 11% of revenue, which could help stabilize some of the stock’s volatility. With a current beta of roughly 2.4, HIMS has historically been considerably more sensitive to broad-market moves than the overall market.

One Comment on CVS's Earnings Call Sent the Stock Tumbling

Authored by Chris Markoch. Article Posted: 8/7/2026.

CVS Health Corp. (NYSE: CVS) delivered a strong earnings report on Aug. 5, but one note revealed during the earnings conference call sent CVS down 5% in trading that day.

In the long run, that note shouldn’t affect what was otherwise a strong beat-and-raise quarter. However, CVS is up more than 50% over the last 12 months and more than 20% in 2026. There were whispers that the stock was “priced for perfection” heading into the report.

Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)

A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.

This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.

Click here to learn this company's name for free today

Immediately after the report, CVS climbed in pre-market trading. That changed during the conference call, when CEO Brian Newman said, “We expect the previously discussed market dynamics in our 340B business to continue and result in a headwind in 2027. Additionally, we believe we will see membership declines in Caremark next year.”

That sent CVS tumbling, but the sell-off raises two questions. First, was this an overreaction to a single data point? Second, at what price should investors consider getting involved?

CVS Delivers a Beat-and-Raise Quarter

Before addressing the two headwinds, the company’s Q2 2026 earnings report was genuinely strong. CVS posted $106.1 billion in total revenue, up from $98.9 billion a year earlier—a 7.3% increase. Adjusted earnings per share (EPS) came in at $2.58, well above last year's $1.81. GAAP EPS more than tripled to $2.31 from 80 cents.

Management also raised its full-year guidance. CVS now expects 2026 adjusted EPS of $7.90 to $8.10, up from its prior range of $7.30 to $7.50. Full-year revenue guidance climbed to at least $414 billion, while cash flow from operations guidance rose to at least $11.5 billion.

Every core segment—Health Care Benefits, Health Services and Pharmacy & Consumer Wellness—posted higher adjusted operating income year over year. By any conventional measure, this was a beat-and-raise quarter, so it’s important to consider the distinct ways management's comments may be weighing on the stock.

Why a Decline in Caremark Membership Matters

Caremark is CVS's pharmacy benefit manager (PBM). These companies have faced intensifying scrutiny for their role in drug pricing, and Wednesday's remark was a reminder of that scrutiny.

On the call, Newman said Caremark specifically—not the broader Health Services segment—is expected to lose members in 2027. According to Newman, the driver is that some health plans that pay Caremark to manage prescription drug benefits are exiting the relationship. That's an issue specific to Caremark, not simply a market-wide contraction.

Newman also tied the decline to industry-wide repricing. CVS, “along with the rest of the industry, is changing the way it prices its services,” he said, referring to the company's ongoing shift toward its TrueCost pricing model. This is a more transparent, cost-plus approach that has been in motion since late 2023.

Newman expressed confidence that the business would settle into “fair margins consistent with historical levels in the industry” over time, but the near-term message was unambiguous: fewer Caremark members in 2027, even as the segment's underlying performance and Q2 pharmacy claims volume (473 million, up from 469 million a year earlier) remained healthy.

The 340B Headwind Could Last Into 2027

Where Caremark membership is a client-retention story, 340B pressure is a distinct regulatory and reimbursement issue. The federal 340B program requires drug manufacturers to sell outpatient medications at reduced prices to hospitals and clinics serving low-income patients.

CVS management said 340B-related market dynamics, largely stemming from manufacturers restricting how those discounted drugs can be distributed, will continue as “a headwind in 2027,” separate from the Caremark membership issue.

Notably, Health Services' Q2 results already reflected 340B pressure, partially offset by “a pull-forward of value previously expected to occur in the second half.” Management said that, after adjusting for the pull-forward, underlying results were in line with expectations, driven by broader Caremark outperformance elsewhere.

In short, 340B is squeezing margins now and is expected to keep doing so into next year. This pressure will be compounded by the separate Caremark membership decline.

CVS Stock Pulls Back After a Powerful Rally

The daily chart shows CVS shares climbing from roughly $70 in April to an intraday high near $112 in July. That was a gain of more than 55% in about three months. Wednesday's decline knocked the stock back to $99.45, still comfortably above its 200-day simple moving average (SMA) of $84.91. The average continues to slope upward, confirming that the longer-term uptrend remains intact.

The MACD, however, tells a more cautious near-term story. The MACD line has fallen to roughly 0.44 while the signal line sits near 1.51, and the histogram has turned negative at about −1.07. The bearish crossover began forming in late July, even before Wednesday's drop.

Volume on the earnings-day sell-off was elevated at more than 18 million shares, signaling institutional participation rather than a thin, low-conviction move. For investors, the setup suggests that short-term momentum has cooled after an extended run, even as the primary trend remains bullish above the 200-day average.

Is the Market Overreacting to CVS Earnings?

The post-earnings reaction to a single data point is a case study in the gap between headline numbers and market perception. The fundamentals indicate that CVS Health had a strong quarter. However, the stock price is flashing a warning.

That disconnect often happens after an extended rally. Investors positioned for continued upside may treat any hint of a future headwind as confirmation that the story is turning, even when the near-term numbers don't support it.

Whether Wednesday's sell-off proves to be an overreaction or an early signal of real Caremark and 340B pressure likely won't be clear for another quarter or two.

Analysts may be the deciding factor. Heading into the report, analysts had been raising their price targets. That means investors shouldn’t get too hung up on the stock trading only slightly below its consensus price target of $105.67. The sell-the-news reaction after earnings shouldn’t change analysts’ sentiment, which is likely to remain positive and potentially move higher.